Discontinued — last reported Q4 '25
Chevron Equity Method Investments decreased by 3.1% to $43.04B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 7.7%, from $46.62B to $43.04B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows an upward trend with a 2.1% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.55B | $41.10B | $40.36B | $41.73B | $43.56B | $45.15B | $44.61B | $46.25B | $46.77B | $48.12B | $46.11B | $47.65B | $47.65B | $47.48B | $46.62B | $49.15B | $48.03B | $44.40B | $43.04B |
| QoQ Change | — | +1.3% | -1.8% | +3.4% | +4.4% | +3.7% | -1.2% | +3.7% | +1.1% | +2.9% | -4.2% | +3.3% | +0.0% | -0.4% | -1.8% | +5.4% | -2.3% | -7.6% | -3.1% |
| YoY Change | — | — | — | — | +7.4% | +9.9% | +10.5% | +10.8% | +7.4% | +6.6% | +3.4% | +3.0% | +1.9% | -1.3% | +1.1% | +3.1% | +0.8% | -6.5% | -7.7% |
| Segment | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 |
|---|---|---|---|---|
| Upstream | $31.20B | $31.62B | $31.47B | $27.74B |
| Downstream | $13.42B | $14.50B | $15.15B | $15.28B |
| Total | $44.61B | $46.11B | $46.62B | $43.04B |
| Segment | Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 |
|---|---|---|---|---|---|
| International | $32.16B | $35.38B | $35.83B | $35.48B | $32.00B |
| Total | $40.36B | $44.61B | $46.11B | $46.62B | $43.04B |